2026. Real World Assessment of Once-a-Month Dosing of Lebrikizumab in Commercial Claims. SKIN The Journal of Cutaneous Medicine. 10, 2 (Mar. 2026), s747. DOI:https://doi.org/10.25251/6b1dka07.